Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827592 · ClinicalTrials.gov registry record · Phase 3
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
NCT01827592 is a Phase 3 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 376 participants.
The verdict
NCT01827592, a Phase 3 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
Study Summary
Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
Interventions
- DRUG Placebo
- DRUG Elobixibat 10 mg
- DRUG Elobixibat 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827592
The ClinicalTrials.gov registry entry for NCT01827592 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01827592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01827592 about?
NCT01827592 is a clinical study titled "26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation". Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
What is the current status of trial NCT01827592?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2013-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01827592?
The interventions under investigation include: Placebo (DRUG), Elobixibat 10 mg (DRUG), Elobixibat 5 mg (DRUG).
Who is sponsoring clinical trial NCT01827592?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.